Merck's cholesterol drug wins European OK

Merck's cholesterol drug Tredaptive--known as Cordaptive in the U.S.--has won European approval. The 1g/20mg modified-release tablets are a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia. That approval comes despite the FDA's recent rejection of the therapy and expectations that the pharma company may have to wait for years before it can get approval to begin marketing in the U.S. There's no clear explanations why regulators are taking such varying stances.

- read the AP story

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.